LADENBURG THALM/SH SH assumed coverage on shares of Tocagen (NASDAQ:TOCA) in a research note released on Wednesday, MarketBeat reports. The firm issued a buy rating and a $20.00 price objective on the stock.
TOCA has been the topic of several other research reports. HC Wainwright initiated coverage on Tocagen in a research report on Monday, June 11th. They set a buy rating and a $14.50 price objective on the stock. Zacks Investment Research cut Tocagen from a buy rating to a hold rating in a research report on Tuesday, May 22nd. B. Riley initiated coverage on Tocagen in a research report on Wednesday, May 16th. They set a buy rating and a $15.00 price objective on the stock. Finally, BidaskClub upgraded Tocagen from a hold rating to a buy rating in a research report on Saturday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $16.90.
Tocagen opened at $9.34 on Wednesday, MarketBeat Ratings reports. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.03. The firm has a market cap of $179.61 million, a price-to-earnings ratio of -3.51 and a beta of 2.43. Tocagen has a fifty-two week low of $8.31 and a fifty-two week high of $14.66.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Thursday, May 10th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. equities analysts expect that Tocagen will post -1.77 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Tocagen by 103.4% in the fourth quarter. California State Teachers Retirement System now owns 28,070 shares of the company’s stock worth $288,000 after purchasing an additional 14,270 shares during the period. BlackRock Inc. increased its position in shares of Tocagen by 36.4% in the fourth quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock worth $10,960,000 after purchasing an additional 285,396 shares during the period. Lake Street Advisors Group LLC bought a new position in shares of Tocagen in the fourth quarter worth $1,042,000. The Manufacturers Life Insurance Company increased its position in shares of Tocagen by 2,075.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company’s stock worth $155,000 after purchasing an additional 14,405 shares during the period. Finally, Goldman Sachs Group Inc. bought a new position in shares of Tocagen in the fourth quarter worth $122,000. Institutional investors own 32.26% of the company’s stock.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.